VxP Pharma Announces Launch of VxP Biologics, Inc. Focusing on the Contract Development & cGMP Manufacturing of Biologics for Clinical Trials at It's US-FDA Audited Sites
Indiana, April 19, 2016 (Newswire.com) - VxP Biologics, Inc. provides comprehensive contract development, and cGMP manufacturing of biologics, at its US-FDA audited facilities in the United States, as well as at its US-FDA audited cGMP facility in India.
Service areas include biologics process development and manufacturing, recombinant DNA engineering, cell line development, protein sciences (purification and crystallography), in-vivo pharmacology and toxicology, as well as cGMP antibody generation. All VxP facilities are US-FDA audited, and are currently serving the global pharmaceutical and biotech industry.
VxP Pharma was founded in 2010 as CRO Solutions, Inc., a sales representation agency representing global Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) from a business development and marketing standpoint. VxP Pharma was launched in 2014 as a platform to promote the combined services of all CRO Solutions clients under a single brand. VxP offers its services to research and development scientists at pharma and biotech companies worldwide, and has a staff of full-time business development representatives covering all major markets, as well as inside sales, technical support, internet marketing, and operations support.
VxP Pharma CEO Raymond E Peck says “The VxP Pharma platform has been extremely successful both for us, and for our global clients. Biologics has become a growing part of our portfolio, so we feel that the creation of VxP Biologics is a natural extension of our service offering, and of our VxP brand.”
VxP is headquartered in Indianapolis, Indiana. To find out more, please visit:
Source: Vxp Biologics
Tags: cGMP manufacturing